Leonie Franziska Maurer
Research Subjects
Leonie Franziska Maurer has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Simon David Kyle
John Radcliffe Hospital, NIHR Oxford Biomedical Research Centre, Oxford, UK
8 shared publications - Colin Alexander Espie
University of Oxford
6 shared publications - Annika Gieselmann
Heinrich Heine University, Dusseldorf, Germany
3 shared publications Noah Lorenz
Mementor DE GmbH, Leipzig, Germany
3 shared publications- Aloysius Niroshan Siriwardena
Community and Health Research Unit, University of Lincoln, Lincoln, UK
2 shared publications - Barbara Robinson
University of Oxford
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Center for Open Science in PsyArXiv
How does Sleep Restriction Therapy work? Testing the Triple-R theory as an explanation through computational modeling
Sleep restriction therapy (SRT) is an effective treatment for insomnia, one of the most prevalent mental disorders today. The Triple-R theory has been proposed to explain the efficacy of SRT based on three processes: restricting time in bed, regulating sleep and wake times, and reconditioning of the bed-sleep association. However, based on the verbal theory alone it is difficult to determine whether the proposed processes explain the efficacy of SRT. In the current paper we test whether Triple-R theory explains the efficacy of SRT through computational modeling. Building on the productive explanation framework we (i) define empirical phenomena in sleep diary data before and after SRT; (ii) formalize the Triple-R theory as a computational model; (iii) test whether the empirical phenomena are reproduced by the model. We show that our computational Triple-R model reproduces most data patterns observed in empirical studies. Therefore, we conclude that the Triple-R theory provides a partial explanation of the efficacy of SRT. Moreover, our proposed Triple-R model makes predictions that can guide new clinical trials and provides a better understanding of the mechanisms of SRT.
- 16 September 2026
- Published by Center for Open Science in PsyArXiv
Open AccessHow does Sleep Restriction Therapy work? Testing the Triple-R theory as an explanation through computational modeling
Sleep restriction therapy (SRT) is an effective treatment for insomnia, one of the most prevalent mental disorders today. The Triple-R theory has been proposed to explain the efficacy of SRT based on three processes: restricting time in bed, regulating sleep and wake times, and reconditioning of the bed-sleep association. However, based on the verbal theory alone it is difficult to determine whether the proposed processes explain the efficacy of SRT. In the current paper we test whether Triple-R theory explains the efficacy of SRT through computational modeling. Building on the productive explanation framework we (i) define empirical phenomena in sleep diary data before and after SRT; (ii) formalize the Triple-R theory as a computational model; (iii) test whether the empirical phenomena are reproduced by the model. We show that our computational Triple-R model reproduces most data patterns observed in empirical studies. Therefore, we conclude that the Triple-R theory provides a partial explanation of the efficacy of SRT. Moreover, our proposed Triple-R model makes predictions that can guide new clinical trials and provides a better understanding of the mechanisms of SRT.
- Open Access
- 9 July 2026
- Published by Wiley in Journal of Sleep Research
- p. e70409
Lost in the System: Identifying Gaps in Adolescent Insomnia Care Using Nationwide Claims Data and a Healthcare Professional Survey
Adolescent insomnia is common, persistent and impairing, yet little is known about how and where young people with sleep difficulties are identified and treated in regular care. Recent calls to prioritise sleep health as a public health imperative underscore the need to understand diagnostic and treatment pathways for those affected. To characterise where adolescents with sleep‐related difficulties are diagnosed, describe patterns of comorbidity and examine healthcare professionals' (HCPs') diagnostic practices, treatment approaches and perceived treatment barriers, we combined nationwide statutory outpatient billing data (2018–2024) for adolescents aged 15–17 years with an online survey of HCPs across clinical disciplines in Germany. Claims data captured incident sleep‐disorder diagnoses and co‐occurring psychiatric conditions. The survey assessed diagnostic procedures, treatment approaches, use of clinical guidelines and perceived systemic constraints. Incident sleep‐disorder diagnoses increased after 2022 and were more common in girls. Comorbid depression and ADHD were frequently coded at first diagnosis, which occurred mostly in general practice. HCPs, however, viewed paediatrics as the typical first contact and primary provider of ongoing care. Sleep‐hygiene counselling was widely used, whereas cognitive‐behavioural therapy for insomnia (CBT‐I) was rarely delivered. Contrary to guideline recommendations, pharmacological treatments were commonly employed. Reported barriers included insufficient specialised providers, diagnostic overshadowing, long waits for CBT‐I and limited consultation time. Current care structures do not reliably support timely recognition or guideline‐concordant management of adolescent insomnia. Priority areas include expanding CBT‐I availability, enhancing referral pathways, improving assessment practices and developing parent‐ and youth‐focused educational resources to support earlier recognition and help‐seeking.
- 9 July 2026
- Published by Wiley in Journal of Sleep Research
- p. e70409
Open AccessLost in the System: Identifying Gaps in Adolescent Insomnia Care Using Nationwide Claims Data and a Healthcare Professional Survey
Adolescent insomnia is common, persistent and impairing, yet little is known about how and where young people with sleep difficulties are identified and treated in regular care. Recent calls to prioritise sleep health as a public health imperative underscore the need to understand diagnostic and treatment pathways for those affected. To characterise where adolescents with sleep‐related difficulties are diagnosed, describe patterns of comorbidity and examine healthcare professionals' (HCPs') diagnostic practices, treatment approaches and perceived treatment barriers, we combined nationwide statutory outpatient billing data (2018–2024) for adolescents aged 15–17 years with an online survey of HCPs across clinical disciplines in Germany. Claims data captured incident sleep‐disorder diagnoses and co‐occurring psychiatric conditions. The survey assessed diagnostic procedures, treatment approaches, use of clinical guidelines and perceived systemic constraints. Incident sleep‐disorder diagnoses increased after 2022 and were more common in girls. Comorbid depression and ADHD were frequently coded at first diagnosis, which occurred mostly in general practice. HCPs, however, viewed paediatrics as the typical first contact and primary provider of ongoing care. Sleep‐hygiene counselling was widely used, whereas cognitive‐behavioural therapy for insomnia (CBT‐I) was rarely delivered. Contrary to guideline recommendations, pharmacological treatments were commonly employed. Reported barriers included insufficient specialised providers, diagnostic overshadowing, long waits for CBT‐I and limited consultation time. Current care structures do not reliably support timely recognition or guideline‐concordant management of adolescent insomnia. Priority areas include expanding CBT‐I availability, enhancing referral pathways, improving assessment practices and developing parent‐ and youth‐focused educational resources to support earlier recognition and help‐seeking.
- Open Access
- 20 March 2025
- Published by Springer Nature in Somnologie
- p. 1-8
Real-world evidence for the use of digital cognitive behavioural therapy for insomnia within primary care
Background: The introduction of digital health applications (DiGAs) in the German healthcare system has enabled scalable access to guideline-recommended treatment for chronic insomnia. Since October 2020, the DiGA somnio has been available for prescription by practitioners offering digital cognitive behavioural therapy for insomnia (CBT-I) for patients with an insomnia diagnosis. The availability of user data now allows us to investigate the effects of digital CBT‑I as part of standard care for the first time. Objective: An analysis of user data derived from the digital CBT‑I intervention somnio will provide a more comprehensive understanding of its impact, benefits, and acceptability within primary care. Materials and methods: We analysed data from N = 5000 randomly selected users who completed somnio between 2021 and 2022 and reported an insomnia severity index (ISI) score ≥ 8 at the start of the intervention. Insomnia severity (ISI) and sleep behaviour were evaluated descriptively over the course of the digital intervention. Cohen’s d for within-group changes was calculated to provide information on effect measures. Results: Our analysis revealed a reduction in insomnia severity of −8.49 ± 5.39 points on the ISI between the start and the end of the programme (d = 1.58). At completion, 57% met the response criteria (reduction ≥ 8 points on the ISI) and 38% met the criteria for remission (ISI < 8). Evaluation of diary entries showed a large improvement in sleep continuity and quality over time (ds = 0.68–1.07). Conclusion: Consistent with controlled studies, our real-world data suggest that digital CBT-I can yield clinically meaningful improvements in sleep and the ISI. The results support implementation of digital therapeutics within primary care.
- 20 March 2025
- Published by Springer Nature in Somnologie
- p. 1-8
Open AccessReal-world evidence for the use of digital cognitive behavioural therapy for insomnia within primary care
Background: The introduction of digital health applications (DiGAs) in the German healthcare system has enabled scalable access to guideline-recommended treatment for chronic insomnia. Since October 2020, the DiGA somnio has been available for prescription by practitioners offering digital cognitive behavioural therapy for insomnia (CBT-I) for patients with an insomnia diagnosis. The availability of user data now allows us to investigate the effects of digital CBT‑I as part of standard care for the first time. Objective: An analysis of user data derived from the digital CBT‑I intervention somnio will provide a more comprehensive understanding of its impact, benefits, and acceptability within primary care. Materials and methods: We analysed data from N = 5000 randomly selected users who completed somnio between 2021 and 2022 and reported an insomnia severity index (ISI) score ≥ 8 at the start of the intervention. Insomnia severity (ISI) and sleep behaviour were evaluated descriptively over the course of the digital intervention. Cohen’s d for within-group changes was calculated to provide information on effect measures. Results: Our analysis revealed a reduction in insomnia severity of −8.49 ± 5.39 points on the ISI between the start and the end of the programme (d = 1.58). At completion, 57% met the response criteria (reduction ≥ 8 points on the ISI) and 38% met the criteria for remission (ISI < 8). Evaluation of diary entries showed a large improvement in sleep continuity and quality over time (ds = 0.68–1.07). Conclusion: Consistent with controlled studies, our real-world data suggest that digital CBT-I can yield clinically meaningful improvements in sleep and the ISI. The results support implementation of digital therapeutics within primary care.
- Open Access
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Digital CBT‐I in Comorbid Insomnia and Depression: Clinical Outcomes From a Pragmatic Randomized Controlled Trial
Depression affects 8.1% of the German population annually, yet many patients remain resistant to conventional treatments. Given that 85% of individuals with depression also experience chronic insomnia, sleep may represent both a contributing and modifiable treatment factor. This study examines whether adding a fully automated digital cognitive behavioral therapy for insomnia (dCBT‐I) to care‐as‐usual (CAU) improves depressive symptoms. Participants with comorbid depression and insomnia were randomized to either the intervention group (dCBT‐I) or the waiting group (WLC). The intervention was delivered via a mobile app or web platform, consisting of 10 sequential core modules based on evidence‐based CBT‐I techniques. Assessments took place at baseline, 12‐ and 24‐weeks post randomization. The primary outcome was the severity of depressive symptoms (Patient Health Questionnaire‐9; PHQ‐9). Secondary outcomes included insomnia severity, daytime sleepiness, fatigue, well‐being and mechanistic effect measures. Linear mixed models were calculated to determine between‐group effects. A total of 140 participants (120 women, mean age: M = 39.76 ± 11.65 years) were randomized to dCBT‐I ( n = 70) or WLC ( n = 70). Large treatment effects at 12‐ and 24 weeks showed significant reductions in depressive symptoms (−3.34 and −2.83; p s d s = 0.66–0.78) in the dCBT‐I group. Treatment effects in favor of dCBT‐I were also found for insomnia severity ( d s = 1.46–1.94) and most secondary outcomes ( d s = 0.33–1.14). This study demonstrates that digital dCBT‐I can be effective not only for individuals with primary insomnia but also for those with depression. These findings align with previous research, highlighting the crucial role of sleep disturbances in depression management. Moreover, the effects remained stable even in the heterogeneous sample investigated in this study, reinforcing the robustness of dCBT‐I across diverse patient groups. Thus, dCBT‐I emerges as a promising adjunctive treatment. Considering these findings, it is essential to explore the integration of sleep‐focused interventions into standard depression treatment. Trial Registration: German Clinical Trial Registry identifier: DRKS00030919
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Open AccessDigital CBT‐I in Comorbid Insomnia and Depression: Clinical Outcomes From a Pragmatic Randomized Controlled Trial
Depression affects 8.1% of the German population annually, yet many patients remain resistant to conventional treatments. Given that 85% of individuals with depression also experience chronic insomnia, sleep may represent both a contributing and modifiable treatment factor. This study examines whether adding a fully automated digital cognitive behavioral therapy for insomnia (dCBT‐I) to care‐as‐usual (CAU) improves depressive symptoms. Participants with comorbid depression and insomnia were randomized to either the intervention group (dCBT‐I) or the waiting group (WLC). The intervention was delivered via a mobile app or web platform, consisting of 10 sequential core modules based on evidence‐based CBT‐I techniques. Assessments took place at baseline, 12‐ and 24‐weeks post randomization. The primary outcome was the severity of depressive symptoms (Patient Health Questionnaire‐9; PHQ‐9). Secondary outcomes included insomnia severity, daytime sleepiness, fatigue, well‐being and mechanistic effect measures. Linear mixed models were calculated to determine between‐group effects. A total of 140 participants (120 women, mean age: M = 39.76 ± 11.65 years) were randomized to dCBT‐I ( n = 70) or WLC ( n = 70). Large treatment effects at 12‐ and 24 weeks showed significant reductions in depressive symptoms (−3.34 and −2.83; p s d s = 0.66–0.78) in the dCBT‐I group. Treatment effects in favor of dCBT‐I were also found for insomnia severity ( d s = 1.46–1.94) and most secondary outcomes ( d s = 0.33–1.14). This study demonstrates that digital dCBT‐I can be effective not only for individuals with primary insomnia but also for those with depression. These findings align with previous research, highlighting the crucial role of sleep disturbances in depression management. Moreover, the effects remained stable even in the heterogeneous sample investigated in this study, reinforcing the robustness of dCBT‐I across diverse patient groups. Thus, dCBT‐I emerges as a promising adjunctive treatment. Considering these findings, it is essential to explore the integration of sleep‐focused interventions into standard depression treatment. Trial Registration: German Clinical Trial Registry identifier: DRKS00030919
- Open Access
- 1 August 2024
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 28 (36) , 1-107
Nurse-delivered sleep restriction therapy to improve insomnia disorder in primary care: the HABIT RCT
Background: Insomnia is a prevalent and distressing sleep disorder. Multicomponent cognitive–behavioural therapy is the recommended first-line treatment, but access remains extremely limited, particularly in primary care where insomnia is managed. One principal component of cognitive–behavioural therapy is a behavioural treatment called sleep restriction therapy, which could potentially be delivered as a brief single-component intervention by generalists in primary care. Objectives: The primary objective of the Health-professional Administered Brief Insomnia Therapy trial was to establish whether nurse-delivered sleep restriction therapy in primary care improves insomnia relative to sleep hygiene. Secondary objectives were to establish whether nurse-delivered sleep restriction therapy was cost-effective, and to undertake a process evaluation to understand intervention delivery, fidelity and acceptability. Design: Pragmatic, multicentre, individually randomised, parallel-group, superiority trial with embedded process evaluation. Setting: National Health Service general practice in three regions of England. Participants: Adults aged ≥ 18 years with insomnia disorder were randomised using a validated web-based randomisation programme. Interventions: Participants in the intervention group were offered a brief four-session nurse-delivered behavioural treatment involving two in-person sessions and two by phone. Participants were supported to follow a prescribed sleep schedule with the aim of restricting and standardising time in bed. Participants were also provided with a sleep hygiene leaflet. The control group received the same sleep hygiene leaflet by e-mail or post. There was no restriction on usual care. Main outcome measures: Outcomes were assessed at 3, 6 and 12 months. Participants were included in the primary analysis if they contributed at least one post-randomisation outcome. The primary end point was self-reported insomnia severity with the Insomnia Severity Index at 6 months. Secondary outcomes were health-related and sleep-related quality of life, depressive symptoms, work productivity and activity impairment, self-reported and actigraphy-defined sleep, and hypnotic medication use. Cost-effectiveness was evaluated using the incremental cost per quality-adjusted life-year. For the process evaluation, semistructured interviews were carried out with participants, nurses and practice managers or general practitioners. Due to the nature of the intervention, both participants and nurses were aware of group allocation. Results: We recruited 642 participants (n = 321 for sleep restriction therapy; n = 321 for sleep hygiene) between 29 August 2018 and 23 March 2020. Five hundred and eighty participants (90.3%) provided data at a minimum of one follow-up time point; 257 (80.1%) participants in the sleep restriction therapy arm and 291 (90.7%) participants in the sleep hygiene arm provided primary outcome data at 6 months. The estimated adjusted mean difference on the Insomnia Severity Index was −3.05 (95% confidence interval −3.83 to −2.28; p < 0.001, Cohen’s d = −0.74), indicating that participants in the sleep restriction therapy arm [mean (standard deviation) Insomnia Severity Index = 10.9 (5.5)] reported lower insomnia severity compared to sleep hygiene [mean (standard deviation) Insomnia Severity Index = 13.9 (5.2)]. Large treatment effects were also found at 3 (d = –0.95) and 12 months (d = −0.72). Superiority of sleep restriction therapy over sleep hygiene was evident at 3, 6 and 12 months for self-reported sleep, mental health-related quality of life, depressive symptoms, work productivity impairment and sleep-related quality of life. Eight participants in each group experienced serious adverse events but none were judged to be related to the intervention. The incremental cost per quality-adjusted life-year gained was £2075.71, giving a 95.3% probability that the intervention is cost-effective at a cost-effectiveness threshold of £20,000. The process evaluation found that sleep restriction therapy was acceptable to both nurses and patients, and delivered with high fidelity. Limitations: While we recruited a clinical sample, 97% were of white ethnic background and 50% had a university degree, which may limit generalisability to the insomnia population in England. Conclusions: Brief nurse-delivered sleep restriction therapy in primary care is clinically effective for insomnia disorder, safe, and likely to be cost-effective. Future work: Future work should examine the place of sleep restriction therapy in the insomnia treatment pathway, assess generalisability across diverse primary care patients with insomnia, and consider additional methods to enhance patient engagement with treatment. Trial registration: This trial is registered as ISRCTN42499563. Funding: The award was funded by the National Institute of Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/84/01) and is published in full in Health Technology Assessment; Vol. 28, No. 36. See the NIHR Funding and Awards website for further award information.
- 1 August 2024
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 28 (36) , 1-107
Open AccessNurse-delivered sleep restriction therapy to improve insomnia disorder in primary care: the HABIT RCT
Background: Insomnia is a prevalent and distressing sleep disorder. Multicomponent cognitive–behavioural therapy is the recommended first-line treatment, but access remains extremely limited, particularly in primary care where insomnia is managed. One principal component of cognitive–behavioural therapy is a behavioural treatment called sleep restriction therapy, which could potentially be delivered as a brief single-component intervention by generalists in primary care. Objectives: The primary objective of the Health-professional Administered Brief Insomnia Therapy trial was to establish whether nurse-delivered sleep restriction therapy in primary care improves insomnia relative to sleep hygiene. Secondary objectives were to establish whether nurse-delivered sleep restriction therapy was cost-effective, and to undertake a process evaluation to understand intervention delivery, fidelity and acceptability. Design: Pragmatic, multicentre, individually randomised, parallel-group, superiority trial with embedded process evaluation. Setting: National Health Service general practice in three regions of England. Participants: Adults aged ≥ 18 years with insomnia disorder were randomised using a validated web-based randomisation programme. Interventions: Participants in the intervention group were offered a brief four-session nurse-delivered behavioural treatment involving two in-person sessions and two by phone. Participants were supported to follow a prescribed sleep schedule with the aim of restricting and standardising time in bed. Participants were also provided with a sleep hygiene leaflet. The control group received the same sleep hygiene leaflet by e-mail or post. There was no restriction on usual care. Main outcome measures: Outcomes were assessed at 3, 6 and 12 months. Participants were included in the primary analysis if they contributed at least one post-randomisation outcome. The primary end point was self-reported insomnia severity with the Insomnia Severity Index at 6 months. Secondary outcomes were health-related and sleep-related quality of life, depressive symptoms, work productivity and activity impairment, self-reported and actigraphy-defined sleep, and hypnotic medication use. Cost-effectiveness was evaluated using the incremental cost per quality-adjusted life-year. For the process evaluation, semistructured interviews were carried out with participants, nurses and practice managers or general practitioners. Due to the nature of the intervention, both participants and nurses were aware of group allocation. Results: We recruited 642 participants (n = 321 for sleep restriction therapy; n = 321 for sleep hygiene) between 29 August 2018 and 23 March 2020. Five hundred and eighty participants (90.3%) provided data at a minimum of one follow-up time point; 257 (80.1%) participants in the sleep restriction therapy arm and 291 (90.7%) participants in the sleep hygiene arm provided primary outcome data at 6 months. The estimated adjusted mean difference on the Insomnia Severity Index was −3.05 (95% confidence interval −3.83 to −2.28; p < 0.001, Cohen’s d = −0.74), indicating that participants in the sleep restriction therapy arm [mean (standard deviation) Insomnia Severity Index = 10.9 (5.5)] reported lower insomnia severity compared to sleep hygiene [mean (standard deviation) Insomnia Severity Index = 13.9 (5.2)]. Large treatment effects were also found at 3 (d = –0.95) and 12 months (d = −0.72). Superiority of sleep restriction therapy over sleep hygiene was evident at 3, 6 and 12 months for self-reported sleep, mental health-related quality of life, depressive symptoms, work productivity impairment and sleep-related quality of life. Eight participants in each group experienced serious adverse events but none were judged to be related to the intervention. The incremental cost per quality-adjusted life-year gained was £2075.71, giving a 95.3% probability that the intervention is cost-effective at a cost-effectiveness threshold of £20,000. The process evaluation found that sleep restriction therapy was acceptable to both nurses and patients, and delivered with high fidelity. Limitations: While we recruited a clinical sample, 97% were of white ethnic background and 50% had a university degree, which may limit generalisability to the insomnia population in England. Conclusions: Brief nurse-delivered sleep restriction therapy in primary care is clinically effective for insomnia disorder, safe, and likely to be cost-effective. Future work: Future work should examine the place of sleep restriction therapy in the insomnia treatment pathway, assess generalisability across diverse primary care patients with insomnia, and consider additional methods to enhance patient engagement with treatment. Trial registration: This trial is registered as ISRCTN42499563. Funding: The award was funded by the National Institute of Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/84/01) and is published in full in Health Technology Assessment; Vol. 28, No. 36. See the NIHR Funding and Awards website for further award information.
- Open Access
- 19 June 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (1) , e14255
Investigating the efficacy of digital cognitive behavioural therapy in comparison to a sleep‐monitoring application via integrated diary and actigraphy: A randomised–controlled trial
Summary: Dissemination of digital cognitive behavioural therapy is a promising approach for treating insomnia in the broad population. Current evidence supports the effectiveness of the digital format, but clinical findings are often limited by the choice of control group and lack of in‐depth therapeutic measures. This study was designed to investigate the specific effects of digital cognitive behavioural therapy in comparison to a self‐monitoring application. Participants meeting criteria for insomnia were randomly allocated (1:1) to 8 weeks of digital cognitive behavioural therapy or 8 weeks of digital sleep monitoring (control application). The primary outcome, insomnia severity, was assessed at baseline, 8‐ and 16‐weeks post‐randomisation. Secondary outcomes included the assessment of sleep via application‐integrated sleep diaries and actigraphy. Linear‐mixed models were fitted to assess between‐group differences. Fifty‐six participants (48 females, mean age: M = 45.55 ± 13.70 years) were randomised to either digital cognitive behavioural therapy (n = 29) or digital sleep monitoring (n = 27). At 8‐ and 16‐weeks post‐randomisation, large treatment effects (d = 0.87–1.08) indicated robust reductions (−3.70 and −2.97, respectively; p ≤ 0.003) in insomnia severity in the digital cognitive behavioural therapy arm, relative to digital sleep monitoring. Treatment effects in favour of digital cognitive behavioural therapy were also found for self‐reported and actigraphy‐derived sleep continuity variables, indicating that sleep improved throughout the 8‐week intervention period. Our study reinforces the role of digital cognitive behavioural therapy in achieving clinical improvements for patients with insomnia, affirming previous findings and supporting the specific effects of cognitive behavioural therapy.
- 19 June 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (1) , e14255
Open AccessInvestigating the efficacy of digital cognitive behavioural therapy in comparison to a sleep‐monitoring application via integrated diary and actigraphy: A randomised–controlled trial
Summary: Dissemination of digital cognitive behavioural therapy is a promising approach for treating insomnia in the broad population. Current evidence supports the effectiveness of the digital format, but clinical findings are often limited by the choice of control group and lack of in‐depth therapeutic measures. This study was designed to investigate the specific effects of digital cognitive behavioural therapy in comparison to a self‐monitoring application. Participants meeting criteria for insomnia were randomly allocated (1:1) to 8 weeks of digital cognitive behavioural therapy or 8 weeks of digital sleep monitoring (control application). The primary outcome, insomnia severity, was assessed at baseline, 8‐ and 16‐weeks post‐randomisation. Secondary outcomes included the assessment of sleep via application‐integrated sleep diaries and actigraphy. Linear‐mixed models were fitted to assess between‐group differences. Fifty‐six participants (48 females, mean age: M = 45.55 ± 13.70 years) were randomised to either digital cognitive behavioural therapy (n = 29) or digital sleep monitoring (n = 27). At 8‐ and 16‐weeks post‐randomisation, large treatment effects (d = 0.87–1.08) indicated robust reductions (−3.70 and −2.97, respectively; p ≤ 0.003) in insomnia severity in the digital cognitive behavioural therapy arm, relative to digital sleep monitoring. Treatment effects in favour of digital cognitive behavioural therapy were also found for self‐reported and actigraphy‐derived sleep continuity variables, indicating that sleep improved throughout the 8‐week intervention period. Our study reinforces the role of digital cognitive behavioural therapy in achieving clinical improvements for patients with insomnia, affirming previous findings and supporting the specific effects of cognitive behavioural therapy.
- Open Access
- 28 February 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (6) , e14180
The effect of single‐component sleep restriction therapy on depressive symptoms: A systematic review and meta‐analysis
Summary: Sleep restriction therapy is a behavioural component within cognitive behavioural therapy for insomnia and is an effective standalone treatment for insomnia, but its effect on depressive symptoms remains unclear. This review aimed to synthesise and evaluate the impact of single‐component sleep restriction therapy on depressive symptoms relative to a control intervention. We searched electronic databases and sleep‐related journals for randomised controlled trials and uncontrolled clinical trials, published from 1 January 1986 until 19 August 2023, that delivered sleep restriction therapy to adults with insomnia. Random‐effects meta‐analysis of standardised mean differences and Cochrane risk of bias assessment were performed on randomised controlled trials, while uncontrolled clinical trials were discussed narratively. The meta‐analysis was pre‐registered on PROSPERO (ID: CRD42020191803). We identified seven randomised controlled trials (N = 1102) and two uncontrolled clinical trials (N = 22). Findings suggest that sleep restriction therapy is associated with a medium effect for improvement in depressive symptoms at post‐treatment (Nc = 6, g = −0.45 [95% confidence interval = −0.70 to −0.21], p < 0.001) and a small effect at follow‐up (Nc = 4, g = −0.31 [95% confidence interval = −0.45 to −0.16], p < 0.001). Five of the seven included randomised controlled trials were judged to have a high risk of bias. Standalone sleep restriction therapy appears to be efficacious for improving depressive symptoms at post‐treatment and follow‐up. However, conclusions are tentative due to the small number of trials and because none of the trials was performed in a population with clinically defined depression. Large‐scale trials are needed to test the effect of sleep restriction therapy in patients experiencing depression and insomnia. Findings also highlight the need to improve the standardisation and reporting of sleep restriction therapy procedures, and to design studies with more rigorous control arms to reduce potential bias.
- 28 February 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (6) , e14180
Open AccessThe effect of single‐component sleep restriction therapy on depressive symptoms: A systematic review and meta‐analysis
Summary: Sleep restriction therapy is a behavioural component within cognitive behavioural therapy for insomnia and is an effective standalone treatment for insomnia, but its effect on depressive symptoms remains unclear. This review aimed to synthesise and evaluate the impact of single‐component sleep restriction therapy on depressive symptoms relative to a control intervention. We searched electronic databases and sleep‐related journals for randomised controlled trials and uncontrolled clinical trials, published from 1 January 1986 until 19 August 2023, that delivered sleep restriction therapy to adults with insomnia. Random‐effects meta‐analysis of standardised mean differences and Cochrane risk of bias assessment were performed on randomised controlled trials, while uncontrolled clinical trials were discussed narratively. The meta‐analysis was pre‐registered on PROSPERO (ID: CRD42020191803). We identified seven randomised controlled trials (N = 1102) and two uncontrolled clinical trials (N = 22). Findings suggest that sleep restriction therapy is associated with a medium effect for improvement in depressive symptoms at post‐treatment (Nc = 6, g = −0.45 [95% confidence interval = −0.70 to −0.21], p < 0.001) and a small effect at follow‐up (Nc = 4, g = −0.31 [95% confidence interval = −0.45 to −0.16], p < 0.001). Five of the seven included randomised controlled trials were judged to have a high risk of bias. Standalone sleep restriction therapy appears to be efficacious for improving depressive symptoms at post‐treatment and follow‐up. However, conclusions are tentative due to the small number of trials and because none of the trials was performed in a population with clinically defined depression. Large‐scale trials are needed to test the effect of sleep restriction therapy in patients experiencing depression and insomnia. Findings also highlight the need to improve the standardisation and reporting of sleep restriction therapy procedures, and to design studies with more rigorous control arms to reduce potential bias.
- Open Access
- 20 September 2023
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (1) , e13982
The effect of sleep restriction therapy for insomnia on REM sleep fragmentation: A secondary analysis of a randomised controlled trial
Summary: Rapid eye movement sleep fragmentation is hypothesised to be a reliable feature of insomnia, which may contribute to emotion dysregulation. Sleep restriction therapy, an effective intervention for insomnia, has the potential to reduce rapid eye movement sleep fragmentation through its manipulation of basic sleep–wake processes. We performed secondary data analysis of a randomised controlled trial to examine whether sleep restriction therapy reduces rapid eye movement sleep fragmentation in comparison to a matched control arm. Participants (n = 56; 39 female, mean age = 40.78 ± 9.08 years) were randomly allocated to 4 weeks of sleep restriction therapy or 4 weeks of time in bed regularisation. Ambulatory polysomnographic recordings were performed at baseline, week 1 and week 4. Arousals during rapid eye movement and non‐rapid eye movement sleep were scored blind to group allocation. The following rapid eye movement sleep fragmentation index was the primary outcome: index 1 = (rapid eye movement arousals + rapid eye movement awakenings + non‐rapid eye movement intrusions)/rapid eye movement duration in hours. Secondary outcomes were two further indices of rapid eye movement sleep fragmentation: index 2 = (rapid eye movement arousals + rapid eye movement awakenings)/rapid eye movement duration in hours; and index 3 = rapid eye movement arousals/rapid eye movement duration in hours. A non‐rapid eye movement fragmentation index was also calculated (non‐rapid eye movement arousals/non‐rapid eye movement duration in hours). Linear‐mixed models were fitted to assess between‐group differences. There was no significant group difference for the primary rapid eye movement fragmentation index at week 1 (p = 0.097, d = −0.31) or week 4 (p = 0.741, d = −0.06). There was some indication that secondary indices of rapid eye movement fragmentation decreased more in the sleep restriction therapy group relative to control at week 1 (index 2: p = 0.023, d = −0.46; index 3: p = 0.051, d = −0.39), but not at week 4 (d ≤ 0.13). No group effects were found for arousals during non‐rapid eye movement sleep. We did not find clear evidence that sleep restriction therapy modifies rapid eye movement sleep fragmentation. Small‐to‐medium effect sizes in the hypothesised direction, across several indices of rapid eye movement fragmentation during early treatment, demand further investigation in future studies.
- 20 September 2023
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (1) , e13982
Open AccessThe effect of sleep restriction therapy for insomnia on REM sleep fragmentation: A secondary analysis of a randomised controlled trial
Summary: Rapid eye movement sleep fragmentation is hypothesised to be a reliable feature of insomnia, which may contribute to emotion dysregulation. Sleep restriction therapy, an effective intervention for insomnia, has the potential to reduce rapid eye movement sleep fragmentation through its manipulation of basic sleep–wake processes. We performed secondary data analysis of a randomised controlled trial to examine whether sleep restriction therapy reduces rapid eye movement sleep fragmentation in comparison to a matched control arm. Participants (n = 56; 39 female, mean age = 40.78 ± 9.08 years) were randomly allocated to 4 weeks of sleep restriction therapy or 4 weeks of time in bed regularisation. Ambulatory polysomnographic recordings were performed at baseline, week 1 and week 4. Arousals during rapid eye movement and non‐rapid eye movement sleep were scored blind to group allocation. The following rapid eye movement sleep fragmentation index was the primary outcome: index 1 = (rapid eye movement arousals + rapid eye movement awakenings + non‐rapid eye movement intrusions)/rapid eye movement duration in hours. Secondary outcomes were two further indices of rapid eye movement sleep fragmentation: index 2 = (rapid eye movement arousals + rapid eye movement awakenings)/rapid eye movement duration in hours; and index 3 = rapid eye movement arousals/rapid eye movement duration in hours. A non‐rapid eye movement fragmentation index was also calculated (non‐rapid eye movement arousals/non‐rapid eye movement duration in hours). Linear‐mixed models were fitted to assess between‐group differences. There was no significant group difference for the primary rapid eye movement fragmentation index at week 1 (p = 0.097, d = −0.31) or week 4 (p = 0.741, d = −0.06). There was some indication that secondary indices of rapid eye movement fragmentation decreased more in the sleep restriction therapy group relative to control at week 1 (index 2: p = 0.023, d = −0.46; index 3: p = 0.051, d = −0.39), but not at week 4 (d ≤ 0.13). No group effects were found for arousals during non‐rapid eye movement sleep. We did not find clear evidence that sleep restriction therapy modifies rapid eye movement sleep fragmentation. Small‐to‐medium effect sizes in the hypothesised direction, across several indices of rapid eye movement fragmentation during early treatment, demand further investigation in future studies.
- Open Access
- 15 September 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (738) , e34-e40
Nurse-delivered sleep restriction therapy in primary care for adults with insomnia disorder: a mixed-methods process evaluation
Background: Sleep restriction therapy (SRT) is a behavioural therapy for insomnia.Aim: To conduct a process evaluation of a randomised controlled trial comparing SRT delivered by primary care nurses plus a sleep hygiene booklet with the sleep hygiene booklet only for adults with insomnia disorder.Design and setting: A mixed-methods process evaluation in a general practice setting.Method: Semi-structured interviews were conducted in a purposive sample of patients receiving SRT, the practice nurses who delivered the therapy, and also GPs or practice managers at the participating practices. Qualitative data were explored using framework analysis, and integrated with nurse comments and quantitative data, including baseline Insomnia Severity Index score and serial sleep efficiency outcomes to investigate the relationships between these.Results: In total, 16 patients, 13 nurses, six practice managers, and one GP were interviewed. Patients had no previous experience of behavioural therapy, needed flexible appointment times, and preferred face-to-face consultations; nurses felt prepared to deliver SRT, accommodating patient concerns, tailoring therapy, and negotiating sleep timings despite treatment complexity and delays between training and intervention delivery. How the intervention produced change was explored, including patient and nurse interactions and patient responses to SRT. Difficulties maintaining SRT, negative attitudes towards treatment, and low self-efficacy were highlighted. Contextual factors, including freeing GP time, time constraints, and conflicting priorities for nurses, with suggestions for alternative delivery options, were raised. Participants who found SRT a positive process showed improvements in sleep efficiency, whereas those who struggled did not.Conclusion: SRT was successfully delivered by practice nurses and was generally well received by patients, despite some difficulties delivering and applying the intervention in practice.
- 15 September 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (738) , e34-e40
Open AccessNurse-delivered sleep restriction therapy in primary care for adults with insomnia disorder: a mixed-methods process evaluation
Background: Sleep restriction therapy (SRT) is a behavioural therapy for insomnia.Aim: To conduct a process evaluation of a randomised controlled trial comparing SRT delivered by primary care nurses plus a sleep hygiene booklet with the sleep hygiene booklet only for adults with insomnia disorder.Design and setting: A mixed-methods process evaluation in a general practice setting.Method: Semi-structured interviews were conducted in a purposive sample of patients receiving SRT, the practice nurses who delivered the therapy, and also GPs or practice managers at the participating practices. Qualitative data were explored using framework analysis, and integrated with nurse comments and quantitative data, including baseline Insomnia Severity Index score and serial sleep efficiency outcomes to investigate the relationships between these.Results: In total, 16 patients, 13 nurses, six practice managers, and one GP were interviewed. Patients had no previous experience of behavioural therapy, needed flexible appointment times, and preferred face-to-face consultations; nurses felt prepared to deliver SRT, accommodating patient concerns, tailoring therapy, and negotiating sleep timings despite treatment complexity and delays between training and intervention delivery. How the intervention produced change was explored, including patient and nurse interactions and patient responses to SRT. Difficulties maintaining SRT, negative attitudes towards treatment, and low self-efficacy were highlighted. Contextual factors, including freeing GP time, time constraints, and conflicting priorities for nurses, with suggestions for alternative delivery options, were raised. Participants who found SRT a positive process showed improvements in sleep efficiency, whereas those who struggled did not.Conclusion: SRT was successfully delivered by practice nurses and was generally well received by patients, despite some difficulties delivering and applying the intervention in practice.
- Open Access
- 10 July 2023
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 46 (11)
The clinical effects of digital cognitive behavioral therapy for insomnia in a heterogenous study sample: results from a randomized controlled trial
Numerous studies worldwide have reported the beneficial effects of digital cognitive behavioral therapy for insomnia (dCBT-I). However, few focus on real-world study samples that reflect people in regular care. To test whether dCBT-I is suitable within German regular care, we designed a randomized controlled trial recruiting a heterogenous insomnia population. Participants aged ≥18 who met the criteria for insomnia disorder were randomized to 8-weeks dCBT-I + care-as-usual (CAU) or they were set on a waitlist + CAU. The intervention group was followed-up at 6- and 12-months. The primary outcome was self-reported insomnia severity, assessed with the Insomnia Severity Index (ISI) at 8-weeks post-randomization. A one-way ANCOVA with baseline score as a covariate was fitted to determine group differences. Secondary outcomes included measures of daytime functioning, quality of life, depression, anxiety, dreams, and nightmares. Of the N = 238 participants (67.6% female), age range 19–81 years, n = 118 were randomized to dCBT-I and n = 120 to the control group. At posttreatment, the use of dCBT-I was associated with a large reduction in the ISI (Diffadj = –7.60) in comparison to WLC (d = –2.08). This clinical improvement was also reflected in responder and remission rates. Treatment effects were also observed for daytime functioning, quality of life, symptoms of depression and anxiety (ds = 0.26–1.02) and at long-term follow-up (intervention group only; ds = 0.18–1.65). No effects were found for dream and nightmare frequency. This study showed that dCBT-I reduces insomnia symptoms and improves daytime functioning in a heterogenous insomnia population in Germany with sustained long-term treatment effects in the intervention group. Our results underscore the potential of digital health applications, their suitability within regular care, and their role in facilitating widespread implementation of CBT-I as a first-line treatment for insomnia.
- 10 July 2023
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 46 (11)
Open AccessThe clinical effects of digital cognitive behavioral therapy for insomnia in a heterogenous study sample: results from a randomized controlled trial
Numerous studies worldwide have reported the beneficial effects of digital cognitive behavioral therapy for insomnia (dCBT-I). However, few focus on real-world study samples that reflect people in regular care. To test whether dCBT-I is suitable within German regular care, we designed a randomized controlled trial recruiting a heterogenous insomnia population. Participants aged ≥18 who met the criteria for insomnia disorder were randomized to 8-weeks dCBT-I + care-as-usual (CAU) or they were set on a waitlist + CAU. The intervention group was followed-up at 6- and 12-months. The primary outcome was self-reported insomnia severity, assessed with the Insomnia Severity Index (ISI) at 8-weeks post-randomization. A one-way ANCOVA with baseline score as a covariate was fitted to determine group differences. Secondary outcomes included measures of daytime functioning, quality of life, depression, anxiety, dreams, and nightmares. Of the N = 238 participants (67.6% female), age range 19–81 years, n = 118 were randomized to dCBT-I and n = 120 to the control group. At posttreatment, the use of dCBT-I was associated with a large reduction in the ISI (Diffadj = –7.60) in comparison to WLC (d = –2.08). This clinical improvement was also reflected in responder and remission rates. Treatment effects were also observed for daytime functioning, quality of life, symptoms of depression and anxiety (ds = 0.26–1.02) and at long-term follow-up (intervention group only; ds = 0.18–1.65). No effects were found for dream and nightmare frequency. This study showed that dCBT-I reduces insomnia symptoms and improves daytime functioning in a heterogenous insomnia population in Germany with sustained long-term treatment effects in the intervention group. Our results underscore the potential of digital health applications, their suitability within regular care, and their role in facilitating widespread implementation of CBT-I as a first-line treatment for insomnia.